Core Insights - Dentsply Sirona Inc. experienced a significant stock surge of approximately 15%, marking its largest single-day increase since 2019, following the release of earnings that exceeded market expectations [1] - The company reported adjusted earnings per share of 43 cents for Q1 2025, surpassing the consensus estimate of 30 cents [1] - Net sales for the first quarter reached $879 million, exceeding the consensus of $854.75 million [1] Financial Performance - First quarter net sales decreased by 7.7% year-over-year, with organic sales declining by 4.4% compared to Q1 2024 [2] - Foreign currency fluctuations negatively impacted net sales by approximately $30 million in Q1 2025 [2] - Adjusted EBITDA increased by 4.2% to $168 million, with the EBITDA margin expanding from 16.8% to 19% [4] Strategic Outlook - The company maintains its guidance for adjusted earnings per share between $1.80 and $2.00, compared to the consensus of $1.82, considering foreign exchange changes and current tariffs [5] - Dentsply Sirona raised its fiscal 2025 sales guidance from a range of $3.50 billion-$3.60 billion to $3.60 billion-$3.70 billion, against a consensus of $3.57 billion [6] - Organic sales are projected to decline by 2.0% to 4.0%, which includes a 2% impact from Byte sales [6] Market Position - Analyst commentary suggests that despite the noise in the profit and loss statement, Dentsply Sirona shares are trading at a material discount to peers, with a valuation of 7 times the projected 2026 EPS [7] - The continued adoption of digital offerings is viewed positively, positioning Dentsply as a potential digital hub for accounts [7]

DENTSPLY SIRONA Inc. (XRAY) reported first-quarter 2025 adjusted earnings per share (EPS) of 43 cents, up by a penny year over year. The bottom line surpassed the Zacks Consensus Estimate by 48.3%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)GAAP EPS in the quarter under review was 10 cents, also up by a penny year over year.DENTSPLY SIRONA’s RevenuesRevenues grossed $879 million in the reported quarter, down 7.7% year over year. However, the metric beat the Zacks Consensus Esti ...

Dentsply International (XRAY) reported $879 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 7.8%. EPS of $0.43 for the same period compares to $0.42 a year ago.The reported revenue represents a surprise of +3.22% over the Zacks Consensus Estimate of $851.55 million. With the consensus EPS estimate being $0.29, the EPS surprise was +48.28%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

Financial Data and Key Metrics Changes - In Q1, the company reported revenue of $879 million, representing a decline of 7.7% year-over-year, with organic sales down 4.4% due to a negative 4% BiTE impact [23][24] - Adjusted EPS for the quarter was $0.43, up 3.7% from the prior year, driven by higher adjusted EBITDA margins and a lower share count [25] - Adjusted EBITDA margins expanded by 220 basis points, benefiting from lower operating expenses and transformational savings [25] Business Line Data and Key Metrics Changes - Essential Dental Solutions segment saw organic sales increase by 0.4%, driven by growth in Europe and the rest of the world, despite lower volumes in the U.S. [27] - Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, primarily due to the loss of a DSO customer in the U.S. and lower lab volumes globally [28] - Connected Technology Solutions segment reported a slight organic sales decline of 0.5%, largely due to CADCAM declines in the U.S., although imaging performance showed growth across all regions [29] Market Data and Key Metrics Changes - U.S. organic sales declined by 14.9%, primarily impacted by a negative 9.8% from BiTE, while imaging growth was noted [31] - Europe saw organic sales increase by 1.1%, driven by strong performance in Germany, particularly in equipment and instruments [34] - Rest of World organic sales grew by 3.1%, with growth in imaging and WellSpec in China, offset by CADCAM declines [35] Company Strategy and Development Direction - The company is focused on driving reliable and sustainable performance, emphasizing customer-centric product innovation and operational efficiency [8][10] - The strategy includes enhancing the digital ecosystem through the DS Core platform, which has gained traction with over 42,000 unique users [14] - The company aims to improve customer engagement through revamped websites and a new e-commerce platform [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating global trade challenges and has developed plans to mitigate potential impacts from tariffs [7][12] - Despite a challenging macroeconomic environment, the company maintained its outlook for organic sales and adjusted EPS for 2025, while increasing reported sales expectations due to foreign currency translation changes [12][36] - Management noted stable patient volume and procedure utilization, although U.S. dentists expressed concerns about economic conditions affecting patient footfall [11] Other Important Information - The company is actively managing its balance sheet and has taken actions to strengthen its position, including entering into a bridge loan agreement [26] - The company has completed the closure of 10 manufacturing and distribution sites as part of its supply chain optimization efforts [23] Q&A Session Summary Question: Can you expand on the tariff impact? - Management indicated that tariffs have been factored into guidance, estimating an annualized impact of approximately $50 million, with about $0.10 impact on EPS [49][50] Question: Update on CFO search? - Management reported good progress in the CFO search, with candidates in the late phases of the process [52] Question: Insights on orthodontics and SureSmile? - Management acknowledged the need to reengage with the orthodontist community and improve user experience for SureSmile [58] Question: Clarification on EBIT margin? - Management noted that Q1 EBIT margin improvements are indicative of future performance, with a focus on judicious SG&A management [62] Question: Cash flow and CapEx expectations? - Management expects CapEx to decrease as ERP projects roll off, leading to improved free cash flow [108]

Financial Data and Key Metrics Changes - In Q1 2025, the company's revenue was $879 million, representing a decline of 7.7% year-over-year. Organic sales decreased by 4.4%, impacted by a negative 4% BiTE effect [23][24]. - Adjusted EBITDA margins expanded by 220 basis points, benefiting from lower operating expenses and transformational savings [25]. - Adjusted EPS for the quarter was $0.43, up 3.7% from the prior year, primarily due to higher adjusted EBITDA margins and a lower share count [25]. Business Line Data and Key Metrics Changes - Essential Dental Solutions segment saw organic sales increase by 0.4%, driven by growth in Europe and the rest of the world, despite lower volumes in the U.S. [26]. - Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, largely due to a negative BiTE impact and a loss of a DSO customer in the U.S. [27]. - Connected Technology Solutions segment had a slight organic sales decline of 0.5%, primarily due to CADCAM declines in the U.S., although imaging performance grew across all regions [28]. Market Data and Key Metrics Changes - U.S. organic sales declined by 14.9%, primarily due to a negative 9.8% impact from BiTE, while imaging growth was noted [30]. - Europe saw organic sales increase by 1.1%, driven by strong performance in Germany, which posted growth for the second consecutive quarter [33]. - The Rest of World segment experienced organic sales growth of 3.1%, with notable growth in imaging and WellSpec in China [34]. Company Strategy and Development Direction - The company is focused on driving reliable and sustainable performance, emphasizing customer-centric product innovation and operational efficiency [7][10]. - The strategy includes enhancing the digital ecosystem through the DS Core platform, which has gained traction with over 42,000 unique users [14]. - The company aims to improve customer engagement and experience through revamped websites and a new e-commerce platform [19][20]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by global trade situations and tariffs but expressed confidence in the company's ability to navigate these risks [6]. - The outlook for 2025 remains unchanged for organic sales and adjusted EPS, with reported sales revised to reflect foreign currency changes [12][35]. - Management noted stable patient volume and procedure utilization, despite some concerns among U.S. dentists regarding economic conditions [11]. Other Important Information - The company is actively managing its balance sheet and has taken steps to strengthen its position, including entering into a bridge loan agreement [25]. - The company has completed the closure of 10 manufacturing and distribution sites as part of its supply chain optimization efforts [23]. Q&A Session Summary Question: Can you expand on the tariff impact? - Management indicated that tariffs have been factored into guidance, estimating a $0.10 impact, with an annualized exposure of about $50 million [47][48]. Question: Update on the CFO search? - Progress is being made with several candidates in the late phases of the process [50]. Question: Insights on the orthodontics side? - Management noted the need to reengage with the orthodontist community and improve user experience with SureSmile [56]. Question: Context behind EBIT margin? - The improvement in Q1 EBIT margin is seen as a reasonable run rate for the rest of the year, with a focus on judicious SG&A management [62]. Question: Cash flow and CapEx expectations? - CapEx is expected to improve as ERP projects roll off, leading to better free cash flow [107].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

Company Performance - Dentsply International reported quarterly earnings of $0.43 per share, exceeding the Zacks Consensus Estimate of $0.29 per share, and showing a slight increase from $0.42 per share a year ago, resulting in an earnings surprise of 48.28% [1] - The company posted revenues of $879 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.22%, although this represents a decline from year-ago revenues of $953 million [2] - Over the last four quarters, Dentsply has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Dentsply shares have declined approximately 27.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $911.58 million, and for the current fiscal year, it is $1.79 on revenues of $3.56 billion [7] - The estimate revisions trend for Dentsply is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which Dentsply belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Dentsply Sirona Reports First Quarter 2025 Results Charlotte, N.C., May 8, 2025 - DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2024. Foreign currency changes negatively impacted first quarter 2025 net sales by approximately ($30) million. Net income was $20 million, or $0.10 per share, compa ...

Financial Performance - Q1 2025 reported sales decreased by (7.7%) to $879 million compared to $953 million in Q1 2024 [17, 18] - Q1 2025 organic sales decreased by (4.4%) driven by an expected (4.0%) Byte impact [7] - Q1 2025 adjusted EBITDA margin expanded by 220 bps to 19.0% compared to 16.8% in Q1 2024 [7, 19] - Q1 2025 adjusted EPS increased by 3.7% to $0.43 compared to $0.42 in Q1 2024 [21, 22] - Q1 2025 operating cash flow decreased by (72%) to $7 million compared to $25 million in Q1 2024 [23, 24] Segment Performance - Essential Dental Solutions (EDS) reported a sales decrease of (2.7%), but organic sales increased by 0.4% to $353 million [26] - Orthodontic and Implant Solutions (OIS) reported a sales decrease of (20.0%), with organic sales down (17.7%) to $217 million, including a ~$40 million Byte impact [26] - Connected Technology Solutions (CTS) reported a sales decrease of (4.7%), with organic sales down (0.5%) to $235 million [26] - Wellspect Healthcare reported a sales increase of 3.4%, with organic sales up 8.0% to $74 million [26] Regional Performance - U S net sales decreased, with organic sales down (14.9%) due to a Byte impact of approximately ($40M) [28, 29] - Europe net sales decreased, with organic sales up 1.1% [28] - Rest of World net sales decreased, with organic sales up 3.1% [28] 2025 Outlook - The company maintains its FY25 outlook for organic sales at (4.0%) to (2.0%) [7, 30] - The company increases its FY25 outlook for reported sales to $3.60 billion - $3.70 billion due to F/X changes [7, 30] - The company maintains its FY25 outlook for adjusted EPS at $1.80 - $2.00 [7, 30]

Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today ann ...